JP2007529507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007529507A5 JP2007529507A5 JP2007503852A JP2007503852A JP2007529507A5 JP 2007529507 A5 JP2007529507 A5 JP 2007529507A5 JP 2007503852 A JP2007503852 A JP 2007503852A JP 2007503852 A JP2007503852 A JP 2007503852A JP 2007529507 A5 JP2007529507 A5 JP 2007529507A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- insulin resistance
- group
- precursor
- sphingolipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 15
- 150000003408 sphingolipids Chemical class 0.000 claims 12
- 239000002243 precursor Substances 0.000 claims 10
- 206010022489 Insulin Resistance Diseases 0.000 claims 8
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 7
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 235000013305 food Nutrition 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000003368 amide group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 230000037213 diet Effects 0.000 claims 2
- 235000005911 diet Nutrition 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 230000002641 glycemic effect Effects 0.000 claims 2
- 230000013632 homeostatic process Effects 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 150000003141 primary amines Chemical group 0.000 claims 2
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 claims 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 150000001323 aldoses Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
- 229930183167 cerebroside Natural products 0.000 claims 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 claims 1
- 229940033329 phytosphingosine Drugs 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 claims 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims 1
- 150000005846 sugar alcohols Chemical class 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04075848.4 | 2004-03-16 | ||
| EP04075848A EP1576894A1 (en) | 2004-03-16 | 2004-03-16 | The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome |
| EP04077088.5 | 2004-07-19 | ||
| EP04077088 | 2004-07-19 | ||
| PCT/NL2005/000193 WO2005087023A1 (en) | 2004-03-16 | 2005-03-15 | The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and metabolic syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007529507A JP2007529507A (ja) | 2007-10-25 |
| JP2007529507A5 true JP2007529507A5 (https=) | 2008-04-24 |
| JP5154218B2 JP5154218B2 (ja) | 2013-02-27 |
Family
ID=34975255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503852A Expired - Fee Related JP5154218B2 (ja) | 2004-03-16 | 2005-03-15 | ２型糖尿病、インスリン抵抗性及びメタボリック症候群の治療及び予防においてスフィンゴ脂質を使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20070207983A1 (https=) |
| EP (1) | EP1729597B1 (https=) |
| JP (1) | JP5154218B2 (https=) |
| AT (1) | ATE500752T1 (https=) |
| AU (1) | AU2005220692A1 (https=) |
| DE (1) | DE602005026785D1 (https=) |
| WO (1) | WO2005087023A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| US8003617B2 (en) * | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
| PL2032134T3 (pl) | 2006-05-09 | 2015-11-30 | Genzyme Corp | Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów |
| US20090117198A1 (en) | 2006-05-31 | 2009-05-07 | Hiroshi Kawakami | Visceral fat accumulation inhibitor, and agent for promoting the increase in and/or inhibiting the decrease in blood adiponectin level |
| EP2594562B1 (en) | 2007-05-31 | 2016-07-20 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| ES2660690T3 (es) | 2007-10-05 | 2018-03-23 | Genzyme Corporation | Método para tratar poliquistosis renales con derivados de ceramida |
| CA2731685A1 (en) | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| EP3078373A1 (en) | 2008-10-03 | 2016-10-12 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitor |
| US8178515B2 (en) * | 2008-10-08 | 2012-05-15 | Nucitec S.A. De C.V. | β-hydroxy-γ-aminophosphonates and methods for the preparation and use thereof |
| JP5689055B2 (ja) * | 2009-05-13 | 2015-03-25 | 丸大食品株式会社 | 鳥皮由来スフィンゴミエリン含有物を有効成分とする抗高血糖及び／又は抗高脂血症剤 |
| JP6169978B2 (ja) * | 2012-01-25 | 2017-07-26 | 株式会社Ｊ−オイルミルズ | スフィンゴイド塩基を含む抽出物の製造方法 |
| US9492466B2 (en) | 2012-06-14 | 2016-11-15 | Nucitec S.A. De C.V. | Beta-hydroxy-gamma-aminophosphonates for treating immune disorders |
| WO2018075622A1 (en) * | 2016-10-19 | 2018-04-26 | University Of Miami | Materials and methods for modulating insulin signaling and preserving podocyte function |
| US10799564B1 (en) | 2019-05-06 | 2020-10-13 | Baxter International Inc. | Insulin premix formulation and product, methods of preparing same, and methods of using same |
| CA3158256A1 (en) * | 2019-11-13 | 2021-05-20 | Aimee EDINGER | Drug formulations and methods of treatment for metabolic disorders |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4952567A (en) * | 1988-05-09 | 1990-08-28 | City Of Hope | Inhibition of lipogenesis |
| IT1235162B (it) * | 1988-12-02 | 1992-06-22 | Fidia Farmaceutici | Derivati di lisosfingolipidi |
| US5190876A (en) * | 1988-12-27 | 1993-03-02 | Emory University | Method of modifying cellular differentiation and function and compositions therefor |
| US5130333A (en) * | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
| JP3157531B2 (ja) * | 1991-03-08 | 2001-04-16 | 昭和産業株式会社 | 血中コレステロール低下剤 |
| US5232837A (en) * | 1991-08-05 | 1993-08-03 | Emory University | Method of altering sphingolipid metabolism and detecting fumonisin ingestion and contamination |
| US5374616A (en) * | 1991-10-18 | 1994-12-20 | Georgetown University | Compositions containing sphingosylphosphorylcholine and the use thereof as a cellular growth factor |
| US6190894B1 (en) * | 1993-03-19 | 2001-02-20 | The Regents Of The University Of California | Method and compositions for disrupting the epithelial barrier function |
| US5478860A (en) * | 1993-06-04 | 1995-12-26 | Inex Pharmaceuticals Corp. | Stable microemulsions for hydrophobic compound delivery |
| US5830853A (en) * | 1994-06-23 | 1998-11-03 | Astra Aktiebolag | Systemic administration of a therapeutic preparation |
| US6773719B2 (en) * | 1994-03-04 | 2004-08-10 | Esperion Luv Development, Inc. | Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias |
| US20020182250A1 (en) * | 1995-09-06 | 2002-12-05 | Goro Hori | Lipid metabolism improving agent |
| AU2195297A (en) * | 1996-02-20 | 1997-09-02 | Sloan-Kettering Institute For Cancer Research | Combinations of pkc inhibitors and therapeutic agents for treating cancers |
| ATE286735T1 (de) * | 1997-04-10 | 2005-01-15 | Kirin Brewery | Verwendung von a-glycosylceramiden zur herstellung eines therapeutischen mittelszur behandlung von autoimmunkrankheiten |
| US6800661B1 (en) * | 1997-04-15 | 2004-10-05 | Board Of Trustees Of The University Of Illinois | Spisulosine compounds |
| US5989803A (en) * | 1997-09-05 | 1999-11-23 | The Trustees Of Columbia University In The City Of New York | Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase |
| JP2001527046A (ja) * | 1997-12-30 | 2001-12-25 | エイプラス サイエンス インベスト アーベー | ガラクトシルセラミド、グルコシルセラミド、ラクトシルセラミド、並びに前糖尿病、糖尿病および／または関連合併症の予防もしくは治療に使用するためのその特定キャッチャー |
| EP1053243B1 (en) * | 1998-02-12 | 2011-03-30 | Emory University | Sphingolipid derivatives and their methods of use |
| CA2362549A1 (en) * | 1999-02-24 | 2000-08-31 | John Hopkins University | Compositions and methods for modulating serum cholesterol |
| WO2001003739A1 (fr) * | 1999-07-12 | 2001-01-18 | Ono Pharmaceutical Co., Ltd. | Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate |
| JP2001213858A (ja) * | 1999-11-24 | 2001-08-07 | Sagami Chem Res Center | スフィンゴシン誘導体 |
| AU784722B2 (en) * | 2000-02-18 | 2006-06-01 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| WO2001072701A1 (en) * | 2000-03-28 | 2001-10-04 | The Liposome Company, Inc. | Ceramide derivatives and method of use |
| US6949247B2 (en) * | 2000-12-28 | 2005-09-27 | Unilever Home & Personal Care Usa Division Of Conopco, Inc. | Stable skin care compositions containing a retinoid and a retinoid booster system |
| JP2002226394A (ja) * | 2001-02-01 | 2002-08-14 | Meiji Milk Prod Co Ltd | 脂質代謝改善組成物 |
| JP4958339B2 (ja) * | 2001-03-21 | 2012-06-20 | 雪印メグミルク株式会社 | 脂質代謝改善剤 |
| DK1406641T3 (da) * | 2001-06-18 | 2009-05-04 | Neptune Technologies & Bioress | Krillekstrakter til forebyggelse og/eller behandling af cardiovaskulære sygdomme |
| US20030109044A1 (en) * | 2001-10-16 | 2003-06-12 | Millennium Pharmaceuticals, Inc. | Methods of using 279, a human G protein-coupled protein receptor |
| JP4568464B2 (ja) * | 2001-11-07 | 2010-10-27 | 雪印乳業株式会社 | 記憶障害予防治療剤 |
| AU2003239489A1 (en) * | 2002-05-17 | 2003-12-02 | Esperion Therapeutics, Inc. | Method of treating dyslipidemic disorders |
| EP1585508B1 (en) * | 2003-01-20 | 2009-04-01 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels |
| JP4585172B2 (ja) * | 2003-01-31 | 2010-11-24 | 森永乳業株式会社 | 骨形成促進剤 |
| US9717754B2 (en) * | 2003-02-27 | 2017-08-01 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
| JP4341891B2 (ja) * | 2003-03-05 | 2009-10-14 | 森永乳業株式会社 | 血糖降下組成物 |
| AU2003217508A1 (en) * | 2003-03-07 | 2004-09-28 | Korea Atomic Energy Research Institute | A composition comprising phytosphingosine or a derivative thereof |
-
2005
- 2005-03-15 US US10/592,994 patent/US20070207983A1/en not_active Abandoned
- 2005-03-15 DE DE602005026785T patent/DE602005026785D1/de not_active Expired - Lifetime
- 2005-03-15 EP EP05722048A patent/EP1729597B1/en not_active Revoked
- 2005-03-15 JP JP2007503852A patent/JP5154218B2/ja not_active Expired - Fee Related
- 2005-03-15 AT AT05722048T patent/ATE500752T1/de not_active IP Right Cessation
- 2005-03-15 AU AU2005220692A patent/AU2005220692A1/en not_active Abandoned
- 2005-03-15 WO PCT/NL2005/000193 patent/WO2005087023A1/en not_active Ceased
-
2009
- 2009-02-11 US US12/369,322 patent/US20090203651A1/en not_active Abandoned
-
2010
- 2010-09-17 US US12/884,607 patent/US20110003772A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007529507A5 (https=) | ||
| JP2006516280A5 (https=) | ||
| US12037317B2 (en) | Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds | |
| US20140056951A1 (en) | Methods and compositions for treating biofilms | |
| JP2004515477A (ja) | Ｎｍｄａレセプターアンタゴニストを用いて神経精神医学的障害を処置するための方法 | |
| JP2018518537A5 (https=) | ||
| JP2011093924A (ja) | （−）−ベンラファキシン誘導体並びにその製造方法および使用方法 | |
| JP2003521470A (ja) | ベンラファキシンの誘導体とその調製および使用方法 | |
| WO2001054728A1 (fr) | NOUVEAUX REMEDES ET UTILISATION D'UN AGONISTE β3 | |
| ES2968840T3 (es) | Compuestos de aminocarbonilcarbamato y su uso en el tratamiento de trastornos hipercinéticos tales como el TDAH | |
| KR20170068629A (ko) | 항코넥신제로서의 플레카이니드의 용도 및 향정신성 약물 효과를 증강시키는 방법 | |
| JP2013533253A (ja) | 双極性障害を治療する方法 | |
| AU2016288230A1 (en) | ADO-resistant cysteamine analogs and uses thereof | |
| US20090005444A1 (en) | Use of propofol prodrugs for treating alcohol withdrawal, central pain, anxiety or pruritus | |
| EA028931B1 (ru) | Композиция, содержащая производные катехоламина, включающие l-2-амино-2,3,3-тридейтеро-3-(3,4-дигидроксифенил) и l-2-амино-2,3-дидейтеро-3-(3,4-дигидроксифенил), или их физиологически приемлемые соли, и применение композиции для лечения болезни паркинсона, синдрома беспокойных ног, бокового амиотрофического склероза и множественной системной атрофии | |
| JP2006516278A5 (https=) | ||
| CN109310669B (zh) | 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途 | |
| EP2475361A1 (en) | N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation | |
| JP7653429B2 (ja) | ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス | |
| US20170119702A1 (en) | Dosage Regimen of Diaryl Sulfide Derivatives | |
| CN103826622B (zh) | 用于预防或治疗情感障碍的n-取代的苯丙酰胺或苯丙烯酰胺 | |
| KR20160146689A (ko) | 파킨슨병을 치료하기 위한 도파민 효능제 및 l-dopa 유도체를 포함하는 조성물 | |
| KR20230039680A (ko) | Hdac 억제 및 급성 신장 손상 후 신장 회복 향상에 사용하기 위한 ptba의 수용성 프로드러그 | |
| JP2007536318A5 (https=) | ||
| JP4433496B2 (ja) | Ａｔｐクエン酸リアーゼの発現抑制用医薬組成物及びその使用 |